Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty (TKA)
A Phase 2 Multicenter, Randomized, Double-blind, Parallel-group, Active-control, Dose-ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 Via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty.
Sponsor: Pacira Pharmaceuticals, Inc
Listed as NCT00485693, this PHASE2 trial focuses on Postoperative Pain and remains completed. Sponsored by Pacira Pharmaceuticals, Inc, it has been updated 11 times since 2007, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jul 2022 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jun 2022 — Jul 2022 [monthly]
Completed PHASE2
-
Apr 2021 — Jun 2022 [monthly]
Completed PHASE2
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Jun 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pacira Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .